Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

October 22, 2026

Company name: TOKAI Corp.
Name of representative: Toshiaki Asai, President & Representative Director
(Securities code: 9729; Prime Market Tokyo Stock Exchange)
Inquiries: Masaru Wada, Corporate Officer, Head of Finance & Corporate Planning Division
(Telephone: +81-58-263-5111)

Notice Regarding Revisions to the Earnings Forecast and Dividend Forecast

TOKAI Corp. (the "Company") hereby announces that at a meeting of its Board of Directors held on October 22, 2026, in light of recent business performance and other factors, it has revised its consolidated earnings forecast and dividend forecast for the full year ending March 31, 2027, announced on May 12, 2026.

1. Revisions to Consolidated Financial Results Forecasts

(1) Revisions to consolidated financial results forecasts for the fiscal year ended March 31,2027 (April 1, 2026 to March 31, 2027)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Net profit per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previously announced forecasts (A)	165,400	8,985	9,437	6,117	198.08
Revised forecasts(B)	167,980	10,286	10,716	6,866	222.25
Change (B-A)	2,580	1,301	1,278	748	—
Change (%)	1.6	14.5	13.5	12.2	—
(Reference) Actual consolidated results for the previous fiscal year (Fiscal year ended March 31, 2026)	159,664	9,382	10,098	6,069	185.61

(2) Rationale for Revising the Earnings Forecast

Regarding the consolidated financial results for the six months ended September 30, 2026, performance has been favorable, particularly in terms of profits, as the prescription unit price in the Dispensing Pharmacy Business has exceeded the plan for both drug fees and technical fees, and the effects of initiatives to efficiently manage rental materials in the Elderly Care Business have continued from the previous fiscal year.

For the third quarter of the fiscal year ending March 31, 2027 and beyond, the strong performance of the Dispensing Pharmacy Business in the first half is expected to continue. In addition, taking into account that the financial results of QLC Produce Corporation which joined the Group in July 2026, will be included in the consolidated financial results from the

third quarter, full-year net sales and profits at all levels are expected to exceed the initial forecast. As a result, operating profit and ordinary profit, which were previously forecast to decrease year on year, are now expected to increase year on year and, together with profit attributable to owners of parent, reach record high.

As a result of this revision to the earnings forecast, the target of ¥9.5 billion in consolidated operating profit set for the fiscal year ending March 31, 2028, the final year of the Medium-term Management Plan, is now expected to be achieved one year ahead of schedule. In the final year of the plan, the Group will continue to work to improve profitability in each business and maximize profits. Specific figures are scheduled to be announced after carefully assessing future macroeconomic trends and business progress.

Note: The above forecasts were prepared based on information that was available at the time of publishing this announcement. Actual results may differ from the forecasted figures due to a variety of factors.

2. Revisions of Dividend Forecasts

(1) Details of Revisions

	Dividend per share		
	Second quarter-end	Fiscal-year end	Total
Previous forecasts	Yen 40.00	Yen 40.00	Yen 80.00
Revised forecasts	40.00	49.00	89.00
Actual consolidated results for the previous fiscal year (Fiscal year ended March 31, 2026)	34.00	34.00	68.00

(2) Rationale of Revisions

The Group considers the return of profits to shareholders to be one of its key management priorities. On May 12, 2026, as part of its basic dividend policy, the Company announced that it would raise the target dividend payout ratio from 35% to 40% and introduce a “progressive dividend” policy to maintain or increase the dividend per share.

In accordance with this basic policy and in light of the revision to the earnings forecast, the Company has revised its year-end dividend forecast for the fiscal year ending March 31, 2027 upward by ¥9 per share from the previous forecast to ¥49 per share.

The interim dividend is scheduled to be submitted to a meeting of the Board of Directors to be held in November 2026, and the year-end dividend is scheduled to be submitted to the 72nd Annual General Meeting of Shareholders to be held in June 2027 for approval.